| Q72611361 | A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer |
| Q28359438 | Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer |
| Q68059396 | Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study |
| Q36705141 | Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators |
| Q40395171 | Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon |
| Q38015061 | Biological response modifiers in the management of patients with breast cancer |
| Q54278364 | Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells. |
| Q67864979 | Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer |
| Q40644174 | Cytokine-based biotherapy of gastrointestinal tumors |
| Q72852182 | Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine |
| Q54994877 | Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5'-deoxy-5-fluorouridine. |
| Q35994010 | Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma |
| Q59616928 | Double modulation of 5-fluorouracil by high-dose leucovorin and interferon?2b in advanced colorectal cancer |
| Q36079721 | Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study |
| Q36665531 | Enhancement of anticancer agent activity by selective inhibitiion of rapidly proliferating tissues of the host |
| Q72108917 | Failure to increase 5-fluorouracil activity with interferon-α2a in the treatment of advanced colorectal cancer |
| Q90044464 | Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin |
| Q41148056 | How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer |
| Q41897991 | Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase |
| Q40935423 | Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance |
| Q67572624 | Interferon alpha-2a shows antitumor activity in combination with 5-fluorouracil against human colon carcinoma xenografts: a study in reference to thymidylate synthetase activity inhibition |
| Q36136350 | Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer |
| Q40390814 | New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase |
| Q70839295 | Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid |
| Q33490745 | Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck |
| Q71469271 | Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer |
| Q35163874 | Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer |
| Q43720420 | Recombinant human interferons alpha, beta and gamma reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells |
| Q40423855 | The role of interferon-α as a modulator of fluorouracil and leucovorin |
| Q47643487 | Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-α: An overview of clinical trials |